Working… Menu

Evaluation of the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes on Insulin Therapy (REVITA-T2Di)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04419779
Recruitment Status : Recruiting
First Posted : June 5, 2020
Last Update Posted : March 29, 2021
Information provided by (Responsible Party):
Fractyl Laboratories, Inc.

Tracking Information
First Submitted Date  ICMJE June 3, 2020
First Posted Date  ICMJE June 5, 2020
Last Update Posted Date March 29, 2021
Actual Study Start Date  ICMJE March 8, 2021
Estimated Primary Completion Date June 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 24, 2021)
The primary endpoint is the percentage of subjects at Week 24 who achieve a HbA1c of </= 7.0% without the need for insulin, DMR vs Sham [ Time Frame: 24 Weeks ]
The primary endpoint will be analyzed using a logistic regression model with terms for baseline insulin dose, baseline HbA1c, change from screening to baseline HbA1c, region (e.g. USA, OUS), baseline FPG, and treatment group.
Original Primary Outcome Measures  ICMJE
 (submitted: June 3, 2020)
Percentage of subjects who achieve a HbA1c ≤ 7.0% at Week 24 without the need for insulin at Week 24, DMR vs Sham. [ Time Frame: 24 Weeks ]
The percentage of patients who achieve a HbA1c ≤ 7.0% at Week 24 without the need for insulin at Week 24, will be analyzed using a logistic regression model with terms for Baseline insulin dose, Baseline HbA1c, Change from Screening to Baseline HbA1c, region (e.g. North America, Europe), Baseline FPG, and Treatment group.
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Evaluation of the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes on Insulin Therapy
Official Title  ICMJE A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita® System in Subjects With Type 2 Diabetes on Insulin Therapy
Brief Summary The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints for patients with Type 2 Diabetes who are inadequately controlled with insulin therapy. The purpose of this study is to demonstrate the efficacy and safety of the Fractyl DMR Procedure using the Revita® System compared to a sham. Subjects randomized to the DMR procedure will be followed per protocol till 48 weeks post treatment. Subjects in the Sham treatment arm will be offered cross over to receive the DMR treatment at 48 weeks and will be followed per protocol for 24 weeks post treatment.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Type 2 Diabetes
Intervention  ICMJE
  • Device: Duodenal Mucosal Resurfacing (DMR)
    The Fractyl DMR Procedure utilizes the Revita® Catheter to perform hydrothermal ablation of the duodenum. The Catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-musical space, followed by an ablation of the duodenal mucosa. Subjects who receive the DMR treatment are followed for 48 weeks post treatment.
  • Device: Duodenal Mucosal Resurfacing (Sham)
    The Sham procedure consists of placing the Revita® Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient. Subjects who receive the Sham procedure are followed for 48 weeks post treatment and are offered cross over to undergo the DMR procedure at 48 weeks and are followed for further 24 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.
Study Arms  ICMJE
  • Active Comparator: Duodenal Mucosal Resurfacing (DMR)
    Duodenal Mucosal Resurfacing (DMR) treatment will include hydrothermal ablation of the duodenal muscosa in an upper endoscopic procedure in patients with type 2 diabetes on insulin.
    Intervention: Device: Duodenal Mucosal Resurfacing (DMR)
  • Sham Comparator: Duodenal Mucosal Resurfacing Sham (Sham)
    Duodenal Mucosal Resurfacing Sham (Sham) treatment will include an upper endoscopic procedure similar to DMR treatment without hydrothermal ablation of the duodenal mucosa in patients with type 2 diabetes on insulin.
    Intervention: Device: Duodenal Mucosal Resurfacing (Sham)
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: October 7, 2020)
Original Estimated Enrollment  ICMJE
 (submitted: June 3, 2020)
Estimated Study Completion Date  ICMJE January 2025
Estimated Primary Completion Date June 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Male; and Non-pregnant, Non-lactating Females
  2. Age between 21 and 70 years (both inclusive)
  3. Subjects with type 2 diabetes on stable doses of metformin (maximum tolerated dose) requiring a minimum of 20 units up to a maximum of 60 units of basal insulin; OR Subjects currently on basal insulin (20-60 units/day) who meet other inclusion criteria but are on other ADAs (including GLP-1a, DPP4, etc) are eligible following an 8-week washout period and initiating on Metformin if not already on it.
  4. Glycosylated Hemoglobin A1c (HbA1c) of 7.5-9.5% (both inclusive) confirmed at the end of at least 3-week stable run in period.
  5. FPG ≥180 to <270 mg/dl (measured after overnight 8 hr fasting and at least 36 hours after the last evening dose of glargine or at least 12 hours after the last dose of NPH insulin)
  6. Body Mass Index (BMI) ≥ 28 and ≤ 40 kg/m2
  7. Women of Child-bearing potential (WOCBP) should have negative urine beta hCG pregnancy test and must agree to use two of the established contraceptive methods throughout the study duration
  8. Able to sign an informed consent form and comply with study requirements.

Exclusion Criteria:

  1. HbA1c <7.5 or >9.5% and/or <180mg or FPG ≥ 270 mg/dl, confirmed by laboratory measurement, after overnight 8hr fasting (off insulin) after at least 3 weeks stable run-in period.
  2. Known case of absolute insulin deficiency as indicated by clinical assessment, and a fasting plasma C-peptide of <0.6 ng/ml
  3. Any drugs or concomitant medications (such as psychoactive drugs such as carbamazepine, phenobarbital, sympathomimetics, corticosteroids and sex hormones, etc.) that can interfere with glucose metabolism
  4. Subjects who have a known or documented SGLT2i and/or Metformin intolerance prior to the study
  5. Recurrent or severe urinary tract or genital mycotic infections or history of genitourinary infection within 4 weeks prior to informed consent
  6. ALT >3 times upper limit normal values unless the findings are consistent with Gilberts disease or if associated with underlying NAFLD.
  7. Use of an investigational drug within 1 month or 5 half-lives (whichever is longer) before the screening
  8. Diagnosed with Type 1 Diabetes or with a recent history of ketoacidosis
  9. Ketosis-prone Type 2 Diabetes
  10. History of non healing diabetic ulcers or amputations
  11. History of more than 1 severe hypoglycemia episode or unawareness within past 6 months of screening
  12. Known intestinal autoimmune disease, as evidenced by either a positive Anti-GAD test, including Celiac disease, or pre-existing symptoms of lupus erythematosus, scleroderma or other autoimmune connective tissue disorder, which affects the small intestine
  13. Secondary hypothyroidism or inadequately controlled primary hypothyroidism (TSH value outside the normal range at screening)
  14. Known history of thyroid cancer or hyperthyroidism who have undergone treatment within past 12 months or inadequately controlled hyperthyroidism
  15. An uncontrolled endocrine condition such as multiple endocrine neoplasia etc (except type 2 diabetes)
  16. Known history of a structural or functional disorder of the esophagus, including any swallowing disorder, esophageal chest pain disorders, or drug-refractory esophageal reflux symptoms, active and uncontrolled GERD (grade 3 esophagitis or greater)
  17. Known history of a structural or functional disorder of the stomach, including gastric ulcer, chronic gastritis, gastric varices, (a large hiatal hernia or type II and higher paraoesophageal hernia) cancer or any other disorder of the stomach
  18. Previous GI surgery that could affect the ability to treat the duodenum such as subjects who have had a Billroth 2, Roux-en-Y gastric bypass, gastric sleeve or other similar procedures or conditions
  19. Known history of chronic pancreatitis or a recent history of acute pancreatitis within the past year
  20. Presence of acute or chronic Hepatitis B or C (except if Hep C is cured) of Cirrhosis; or hepatic decompensation/acute liver disease during the last 6 months; or alcoholic or autoimmune chronic hepatitis.
  21. Symptomatic gallstones or symptomatic kidney stones, acute cholecystitis
  22. Clinically active systemic infection
  23. Known immunocompromised status, including but not limited to individuals who have undergone organ transplantation, chemotherapy or radiotherapy within the past 12 months, who have clinically-significant leukopenia, who are positive for the human immunodeficiency virus (HIV) , who are on potential immunosuppressants or whose immune status makes the subject a poor candidate for clinical trial participation in the opinion of the Investigator
  24. History of malignancy within the past 5 years
  25. Known active coagulopathy, or current upper gastro-intestinal bleeding conditions such as ulcers, gastric varices, strictures, or congenital or acquired intestinal telangiectasia
  26. Subjects with active helicobacter pylori infection (Subjects may be enrolled if they had history of h pylori infection and were successfully treated)
  27. Known cases of anemia, thalassemia or conditions that affect RBC turnover such as recent blood transfusion within 90 days
  28. Use of anticoagulation therapy (such as warfarin, coumadin, NOAC) or anti platelet agents (such as thienopyridine) which cannot be discontinued for 5-7 days or 2 drug half-lives before and the procedure
  29. Use of systemic glucocorticoids (excluding topical or ophthalmic application or inhaled forms) for more than 10 consecutive days within 90 days prior to the Screening Visit.
  30. Use of drugs known to affect GI motility (e.g. Metoclopramide)
  31. History of moderate to severe chronic kidney disease (CKD), with estimated glomerular filtration rate (eGFR) <45 ml/min/1.73m2 (estimated by Modification of Diet in Renal Disease [MDRD]) or end stage renal failure or on dialysis
  32. History of Myocardial Infarction, Stroke, or major event requiring hospitalization within the last 3 months prior to screening
  33. History of new or worsening signs or symptoms of CHD within the last 3 months
  34. Known case of severe peripheral vascular disease
  35. Known case of heart failure requiring pharmacologic therapy
  36. Clinically significant ECG findings such as new clinically significant arrythmia or conduction disturbances that increases risk and requires intervention as determined by the investigator
  37. Fasting triglyceride value of >600 mg/dL (increases risk of pancreatitis)
  38. Participating in a weight loss program and is currently not in the maintenance phase
  39. General contraindications to deep or conscious sedation or general anesthesia or high risk as determined by anesthesiologist (e.g. ASA score 4 or higher) or contraindications to upper GI Endoscopy
  40. History of any illicit alcohol or substance abuse
  41. Use of weight loss medication such as Meridia, Xenical, or over the counterweight loss medications or other prescribed medications used specifically for purpose of weight loss.
  42. Use of Dietary supplements or herbal preparations that may have unknown effects on glycemic control, risk of bleeding
  43. Participating in another ongoing clinical trial of an investigational drug or device
  44. History of non-adherence to treatment in the previous 6 months, as determined by the investigator based on patient history, HbA1C value and/or drug accountability.
  45. Any other mental or physical condition which, in the opinion of the investigator, makes the subject a poor candidate for clinical trial participation
  46. Unwilling or unable to perform self-monitoring of blood glucose (SMBG), complete the patient diary, or comply with study visits and other study procedures as required per protocol.
  47. Recovered from severe COVID 19 infection within 6 months or those who have persistent long COVID-19 symptoms (i.e. they have not recovered for several weeks or months since start of symptoms that were suggestive of COVID-19 irrespective if they are tested or not.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 21 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Sarah Hackett 781-902-8840
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT04419779
Other Study ID Numbers  ICMJE C-00044
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Fractyl Laboratories, Inc.
Study Sponsor  ICMJE Fractyl Laboratories, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Fractyl Laboratories, Inc.
Verification Date March 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP